Ondine Biomedical

Ondine Biomedical Inc. is a biotechnology company specializing in the development and commercialization of non-antibiotic therapies aimed at treating bacterial, viral, and fungal infections. Utilizing its patented Photodisinfection technology, which employs light-activated antimicrobial mechanisms, the company addresses the growing concern of antibiotic resistance. Ondine Biomedical's primary offerings include Periowave, an adjunctive treatment for chronic adult periodontitis, and the MRSAid Photodisinfection system, designed to eliminate methicillin-resistant Staphylococcus aureus from nasal passages. Additionally, the company has developed Endowave, targeted at eradicating bacterial biofilms in endotracheal tubes, and Vitalwave, which seeks to decolonize the birth canal to prevent transmission of pathogens during childbirth. The company also collaborates with Sinuwave Technologies Corporation on therapies for chronic sinusitis. Headquartered in Vancouver, Canada, Ondine Biomedical was previously known as Ondine Biopharma Corporation until it rebranded in October 2010.